Abstract-A broad array of nanomaterials is available for use as contrast agents for molecular imaging and drug delivery. Due to the lack of endogenous background signal in vivo and the high NMR sensitivity of the 19
F atom, liquid perfluorocarbon nanoemulsions make ideal agents for cellular and magnetic resonance molecular imaging. The perfluorocarbon core material is surrounded by a lipid monolayer which can be functionalized with a variety of agents including targeting ligands, imaging agents and drugs either individually or in combination. Multiple copies of targeting ligands (~20-40 monoclonal antibodies or 200-400 small molecule ligands) serve to enhance avidity through multivalent interactions while the composition of the particle's perfluorocarbon core results in high local concentrations of 19 F. Additionally, lipophilic drugs contained within molecularly targeted nanoemulsions can result in contact facilitated drug delivery to target cells. Ultimately, the dual use of perfluorocarbon nanoparticles for both site targeted drug delivery and molecular imaging may provide both imaging of disease states as well as conclusive evidence that drug delivery is localized to the area of interest. This review will focus on liquid perfluorocarbon nanoparticles as 19 F molecular imaging agents and for targeted drug delivery in cancer and cardiovascular disease.
INTRODUCTION
Perfluorocarbons (PFCs) are synthetic organic compounds in which all or most of the hydrogen atoms have been replaced with fluorine atoms. These molecules have the unique property of being both lipophobic and hydrophobic. The use of perfluorocarbons has been explored for various medical applications, including percutaneous transluminal cardiac angioplasty (PTCA), 7, 20 partial liquid lung ventilation, 8, 17, 24 gastrointestinal X-ray contrast agent, 3, 54 and blood substitutes. 6, 14, 22, 31, 42 As an example, Fluosol Ò from Green Cross was approved for intravascular use in the United States, and contains perfluorodecalin.
The tissue clearance time for perfluorocarbons varies based on the chemical compound. These tissue half-lives ranges from 4 days for perfluorooctylbromide (PFOB) to 65 days for perfluorotripropylamine. Clearance of these fluorocarbons takes place not through metabolism, but through slow dissolution back into the circulation by lipid carriers. Ultimately perfluorocarbons are eliminated through expiration. 37, 43, 56 The design of targeted nanoscale molecular imaging agents must accomplish a long circulating half-life, sensitive and selective binding to the epitope of interest, prominent contrast-to-noise enhancement, acceptable toxicity, ease of clinical use, and ideally would be applicable with standard commercially available imaging systems. The use of nanoparticles or targeted nanoemulsions as carriers has the additional advantage of selectively delivering large payloads of imaging or therapeutic agents to the site of interest. Nanoscale micelles and surfactant-stabilized nanodroplets of PFCs can be created by self-assembly of molecules to produce agents that can be used for clinical cellular and molecular imaging. 6, 50, 51 NMR utilizing the unique signature from 19 F has been widely exploited for both spectroscopic studies and increasingly for magnetic resonance imaging (MRI). The 19 F atom exhibits high NMR sensitivity, with essentially no background signal within the body. This review will focus on the use of self-assembling liquid PFC nanoparticles for 19 F magnetic resonance molecular imaging and spectroscopy (MRS) and drug delivery in cancer and cardiovascular disease.
F NMR AND MOLECULAR MRI
The liquid perfluorocarbon core material in PFC nanoemulsions is surrounded by a lipid monolayer that can be functionalized to contain various agents for imaging or therapeutic action. Different core perfluorocarbons can be used, including perfluorodichlorooctane, perfluorodecalin, perfluoro 15-crown-5 ether (CE), and most commonly, perfluorooctyl bromide (PFOB). Multifunctional activity can be realized by incorporating combinations of one or more targeting ligands, imaging agents, and/or drugs into the formulation simultaneously. Materials can be covalently or noncovalently linked to the particle surface, dissolved in the coating (e.g., lipophilic drugs deposited in lipid membrane layers), or carried in the particle interiors for cellular deposition and activation (Fig. 1) .
Multiple copies of binding ligands can be incorporated depending on the size of the particle. This serves to enhance avidity and target detectability by reducing the particle dissociation rate thus better securing the agent at the intended site. Typically, 20-40 monoclonal antibodies or 200-400 small molecule ligands can be attached to the surface of the particle. 26, 28 Specificity is conferred by the targeting ligand itself, with dissociation constants generally in the nanomolar range, although high avidity agents may in part overcome this limitation through multivalent interactions.
Once the particle binding takes place, high avidity is conferred through multivalent interactions between the particle and cell surface. Particles that do not bind are conveniently removed by the liver and spleen. The particle size of the emulsion predicts both the vascular half-life and biodistribution. Pharmacokinetic analysis indicates a clearance half-life of approximately 3-6 h depending on species. 18 The tissue distribution reflects the expected activity of the macrophage phagocytic system where the spleen and the liver remove the majority of the particles after intravenous injection. 18 Ultimately, the optimal particle size of the emulsion should result in a vascular persistence that is clinically efficacious while limiting deep-tissue retention, which for most intravenous applications is approximately 200-400 nm.
The comparatively modest MRI contrast enhancement achievable with targeted contrast agents for molecular imaging necessitates the delivery of higher payloads of contrast materials, which can be provided by novel nanotechnologies. For PFC particles, the opportunity to employ a unique MRI/MRS signature emanating from its fluorine ( 19 F) core can be advantageous. 34 Recently, quantitative approaches have been described for molecularly targeted emulsions that allow the computation of concentration of bound nanoparticles under certain circumstances, based on either the 1 H or 19 F signals. 33, 34 NMR is a particularly rich phenomenon providing information through multiple parameters including chemical shift, relaxation processes (R 1 and R 2 ), scalar coupling, and chemical exchange, and each of these parameters has been exploited for specific 19 F NMR reporter molecules. The simplest concept of NMR is that of chemical shift and 19 F is exceptionally sensitive to molecular and micro environmental changes. Fluorine NMR has a very large chemical shift range (~300 ppm) allowing multiple agents to be examined simultaneously with minimal danger of signal overlap. NMR signal can be quantitative, so that the integral of a signal is directly proportional to the amount of material being interrogated. Detection sensitivity is governed by numerous parameters including the volume of interrogation, the required spatial resolution, and relaxation properties of the molecule and its tendency to accumulate or disperse from a region of interest.
The signal generated by the fluorine atoms within the perfluorocarbon core of PFC-based nanoparticles has been introduced as a unique signature for MR molecular imaging. 5, 27, 33, 34, 38 While not all nuclei exhibit the magnetic resonance effect and therefore cannot be measured directly, 19 F, like 1 H, has one unpaired proton and no unpaired neutrons, and thus with a net spin of ½, exhibits the NMR phenomenon. Serendipitously, the gyromagnetic ratio (c) for 19 F is also close to that of 1 H (i.e., 40.1 vs. 42.6 MHz/T, respectively) which means that their resonance frequencies are relatively similar. Their relative signal strengths are also similar, with that of 19 F being approximately 83% that of 1 H. The liquid perfluorocarbon core represents 98% of the total nanoparticle volume, leading to a substantial 19 F concentration (~100 M) within typical perfluorooctylbromide particles.
While the 19 F isotope of fluorine has a natural abundance of near 100%, the biological presence is virtually zero. Therefore, the 19 F nuclei which are highly concentrated within the perfluorocarbon core of the nanoparticle emulsions are a prime candidate for direct MR spectroscopy and imaging without surrounding signal from endogenous fluorine (Fig. 2) . This recent approach has been demonstrated for molecular imaging and spectroscopy of fibrin at 4.7 T and for quantifying the concentration of nanoparticle binding to a selected site based on localized fluorine spectroscopy and subsequently for stem cell imaging in vivo. 33, 34, 40 Another use for 19 F imaging and spectroscopy of perfluorocarbon particles is in recognizing different targeted moieties on the same sample. Due to differences in their local nuclear environments (e.g., electron shielding, J-coupling, etc), different fluorine atoms resonate at slightly different frequencies so that they are often readily separable on an NMR spectrum.
This means that by using PFC nanoparticles formulated with different perfluorocarbon species, it is possible to target them to the same sample and quantify their presence separately with one spectroscopic scan as shown by Morawski et al. 34 in Fig. 3 for PFOB and crown ether compounds formulated as nanoemulsions. The 19 F signal was measured at 4.7 T from fibrin-targeted, paramagnetic perfluorocarbon nanoparticles by Morawski et al. to spectroscopically quantify the varying amounts of PFC nanoparticles bound to thrombi in vitro. The estimates of 19 F concentration based on MRS of 19 F matched the actual measured concentrations of particles. While spectroscopy will ultimately be most useful for quantification, other techniques allow imaging of the different perfluorocarbon particles as well. These may include frequency selective excitation so that only the perfluorocarbon species of interest produces a signal or other forms of chemical shift imaging that have been developed for differentiating fat from water in clinical imaging. 5 
Applications
As an alternative to MR signal modeling or measuring the indirect effects of contrast agents on water molecules (e.g., T1 or T2 for 1 H), one could measure the 19 F signal of the contrast agent directly, as is the case for nuclear medicine radioisotopes. Given their high fluorine content, fibrin-targeted nanoparticles may provide quantification of exposed fibrin, indicating the size and/or number of ruptures in the fibrous cap. This technique was applied to human carotid endarterectomy samples to provide a quantitative measure of microscopic amounts of fibrin associated with ruptured atherosclerotic plaques in patients with carotid artery disease 34 (Fig. 4) Extending this paradigm to a 1.5 T MR system using rapid steady-state imaging techniques, in vitro fibrin-bound nanoparticles of two different species of perfluorocarbon (PFOB and CE) in varying volumes were not only quantified via clinically relevant imaging techniques, but were also identified and independently imaged based on their unique MR spectral signatures. 5 Both imaging and spectroscopy could distinguish nanoparticles containing either perfluorooctylbromide (PFOB) or perfluoro-15-crown-5-ether (CE) as the core material. The signal to noise for PFOB was lower than CE (10 vs. 25, respectively), presumably due to the single CE peak (20 equivalent fluorine atoms) compared to the multiple PFOB peaks (17 fluorine atoms distributed over 5 peaks). A clear linear relationship between the 19 F signal intensity and perfluorocarbon concentration was demonstrated for both PFOB and CE using both imaging and spectroscopy. From this demonstration on fibrin clots, one might extrapolate the potential of using multiple perfluorocarbon nanoparticle agents, each targeted to a different epitope, to perform noninvasive, ''imaging-based immunohistochemistry'', e.g., quantifying simultaneously the amount of angiogenesis and exposed fibrin associated with an atherosclerotic plaque as an indicator of its pathophysiological significance.
The possibility for performing MR angiography with untargeted 19 F PFC nanoparticles has been explored by Morawski-Neubauer et al. 38 Because these agents are sized so as to remain in the vascular space, they might be used to define vessel geometry. This requires sufficient signal sensitivity, which depends in part on blood levels of fluorine. Using a rapid scanning technique (steady state free precession, SSFP) and custom designed coils, high level vascular signals were obtained at 1.5 T for in vitro and ex vivo samples. Also, in vivo imaging of rabbit carotid arteries was successful both during direct intra-arterial injection of agents and after noninvasive intravenous dosing and imaging under steady state conditions. This study represents the first demonstration of small vessel imaging at clinical field strengths with sufficient temporal resolution to view both first pass contrast enhancement and steadystate blood signals for nanoparticles delivered noninvasively at moderate doses. This dosage corresponds to 1.5-2.5 mL emulsion per kg body weight (or, equivalently, 0.5-0.9 g perfluorocarbon per kg) and is well within the ''absolute no effect dose'' of 2.7-9 g PFC/kg determined using other PFC blood substitute emulsions. 14 In addition to molecular imaging of fibrin and MR angiography, 19 perfluorocarbon preparation of nanoparticles to load dendritic immune cells with no loss of viability. The expression of cell surface markers, including CD80 and MHC, was also not affected. Accordingly, they demonstrated an extension of the use of fluorine imaging at research field strengths (11.7 T) to track cells after local and systemic injections. The advantage to this approach is that no tissue background signal exists because there is no appreciable amount of fluorine in the body to confound the signal from the targeted cells.
Partlow et al. 40 reported methods for labeling of proangiogenic endothelial precursor cells with multiple types of perfluorocarbon nanoparticles for rapid imaging and spectroscopy at clinical (1.5 T) and research (11.7 T) field strengths (Fig. 5) . These cells avidly ingest the PFC nanoparticles without the need for conjunctive transfection agents, such as lipofectamine, with no untoward effect on cell viability and preserved ability to contribute to cancer angiogenesis. This is likely due to the specific nature of the soft deformable particles and their interaction with the endothelial progenitor cells. Perfluorocarbon labeling of endothelial progenitor cells can be detected with 19 F spectroscopy on the order of days out to one week depending on the perfluorocarbon used. Moreover, not only can these cells be uniquely identified and tracked with MRI, but their local concentration can be quantified based on the 19 F spectral signature. The capacity of targeted PFC nanoparticles to serve as a universal carrier of imaging agents can be extended to proton T 1 -weighted MR imaging as well as nuclear and optical imaging. Because molecular epitopes of interest may reside on or inside of cells in very sparse quantities at low nanomolar or picomolar concentrations, considerable amplification of the local contrast effect might be achieved by incorporating large amounts of paramagnetic or other relaxing agents as the payload. 33 In the case of T 1 -weighted imaging, the surface of the particle can be decorated with numerous copies of gadolinium chelates (100,000+) to achieve the micromolar concentrations required per voxel. 13 Paramagnetic PFC-based nanoparticles have been shown to yield substantial amplification of signal from fibrin clots at 1.5 T both in vitro and in vivo. 13, 25, 57 In the case of the experimental canine model used by Flacke et al. 13 in vivo contrastto-noise ratios between clot and blood exceeding 100 were achieved. For nuclear imaging, the utility of 111 In-labeled a v b 3 -integrin targeted PFC nanoparticles for the detection of angiogenesis has been demonstrated in the rabbit Vx-2 tumor model. 18 111 In-labeled a v b 3 -integrin targeted PFC nanoparticles yielded high tumor-to-muscle ratio signals, which was enhanced for the formulations with 10 nuclides per particle vs. one. The 111 In-labeled nanoparticles provided a high sensitivity, low-resolution signal from the tumor neovasculature that was easily recognized within 15-30 min after injection and which persisted for hours. Optical detection and ex vivo visualization has been shown with the complexation of fluorescent agents to the PFC nanoparticles. These nanoparticles can generate signals detectable by immunohistochemistry. 9 ,41 These applications demonstrate the capability of this system to produce diverse functionalizations of PFC nanoparticles for molecular imaging using various modalities.
DRUG DELIVERY
The potential dual use of nanoparticles for both imaging and site targeted delivery of therapeutic agents offers great promise for individualizing therapeutics. Image-based therapeutics with site-selective agents could enable conclusive assurance that the drug is reaching the intended target. In the case of particulate agents however, the mechanisms of drug delivery become more complicated such that serum concentrations are not necessarily indicative of the amount of drug accessible to the desired site. Furthermore, by targeting the carrier to the tissue of interest, the drug release is also localized to that area, resulting in a much higher effective drug concentration at the site than is indicated by serum levels alone. The ability to quantify the local concentrations of these particles could be of great benefit for estimating local drug concentrations and developing new pharmacokinetic and pharmacodynamic paradigms to describe this new class of agents.
Mechanism of Nanoparticle Cell Interaction
The unique mechanism of drug delivery for highly lipophilic agents such as paclitaxel contained within perfluorocarbon emulsions depends on the close apposition between the nanoparticle carrier and the targeted cell membrane, and has been described as contact facilitated drug delivery. 27 In contrast to liposomal drug delivery that typically requires endocytosis of entire particles followed by an endosomal release step to liberate the active compounds, the mechanism of drug transport for the PFC particles involves particle binding followed by lipid mixing of the phospholipid surface components between the emulsion vesicle and the targeted cell membrane 9 ( Fig. 6 ). This mechanism depends in part on the extent and frequency of contact between two lipid surfaces and the ability to form a hemifusion complex between the vesicle and the cell lipid layers to achieve the lipid mixing. Drugs, especially hydrophobic moieties con-tained in the lipid monolayer of the nanoparticle, then diffuse out into the cell lipid membrane along with other components (e.g., peptides, genes) of the nanoparticle lipid membrane. 45 Ultimately they are transported to the cytoplasm directly by energy requiring processes that involve lipid raft-dependent internalization but not the internalization of intact particles. 41 This eliminates the requirement of endosomal escape for drug activity.
The rate of lipid exchange and drug delivery can be greatly increased by the application of clinically safe levels of ultrasound energy that increase the propensity for hemifusion or enhance contact between the nanoparticles and the targeted cell membrane 9 ( Fig. 7) . Previously, disruptive ultrasonic methods have been applied to micrometer-sized bubbles to perforate cell membranes by concussive or streaming forces in the hope of enhancing local delivery of drugs, genes and other therapeutic agents through ''temporary'' membrane pores. 11, 16, 47, 49 In contrast, Crowder et al. 9 first reported that noncavitational ultrasound energy can markedly augment delivery of lipophilic substances to selected cell types after molecular targeting, which neither produces nor requires disruption of cell membrane integrity. 9, 44 Ultrasound (mechanical index µ 1.9) applied with a clinical ultrasound imaging system to nanoparticles targeted to a v b 3 integrins on C32 melanoma cancer cells in vitro produced no untoward effects. With ultrasound exposure of 5 min, lipid delivery from the nanoparticles into the cytoplasm of C32 melanoma cells was dramatically augmented. This approach should allow focused delivery of sufficient energy to deep tissue to activate drug deposition from molecularly targeted nanoparticle carriers, while avoiding any potentially harmful bioeffects of the ultrasound per se to the targeted or other surrounding cells. The physical mechanisms responsible for this phenomenon entail the action of quantifiable ''radiation forces'' on particles that are induced by the traveling compressional (ultrasound) waves, 10, 48 which can increase biophysical interactions of nanoparticles with the targeted cell surface. Recent studies by Soman et al. 46 extend this concept to the delivery of bulky therapeutic cargo (nanogold DPPE) with nanoparticles targeted a v b 3 integrins. In these studies, non-cavitational ultrasound used in conjuction with PFC-nanoparticles produced the uptake and delivery of lipids to the cytosol that would otherwise remain on the cell surface. These methods offer additional mechanisms for facilitating targeted drug delivery with the application of exogenous, safe ultrasound energy in conjunction with therapeutic targeted nanoparticles. The success of such ''double targeting'' strategies ultimately may allow the use of even lower systemic doses of highly effective agents.
Therapeutic Applications of Targeted Perfluorocarbon Nanoparticles
The contact facilitated mechanism of targeted drug delivery with the perfluorocarbon nanoparticles was first demonstrated in vitro with PFC particles targeted FIGURE 6. ''Lipid streaming'' into the plasma membrane. A high power image of a cell surface (see inset) shows a bound rhodamine-labeled nanoparticle (red) with adjacent lipid mixing into the plasma membrane of a cell transiently expressing a green cytoplasmic marker. The cellular features that can be observed are the nucleus (dark circular region), cell cytoplasm (green), and plasma membrane (directly adjacent to cell cytoplasm, only small portion is labeled with red lipid from nanoparticle). (Reprinted with permission from Crowder et al. to smooth muscle cells (via tissue factor) delivering antiproliferative therapy (doxorubicin or paclitaxel). These studies indicated a potent antiproliferative effect for paclitaxel regardless of drug loading dose (0.2 or 2.0 mol.%). 27 When untargeted, the paclitaxel-laden nanoparticles exerted no effect on cell proliferation, indicating the requirement for a nanoparticle binding event for efficient drug delivery. Similar observations were made for doxorubicin, although due to its greater water solubility as compared with paclitaxel, some antiproliferative effect was also noted even without selective cell targeting. These initial proof of concept experiments have led to the development of targeted therapeutics using this platform for cardiovascular disease and cancer.
In Vivo Targeted Anti-angiogenic Therapy for Atherosclerosis
Angiogenesis of the vasa vasorum is required for the progression of atherosclerosis and perhaps for the production of unstable plaque. 21, 30, 35, 39 Plaque neovasculature serves as both a biomarker of early disease, a harbinger of vulnerable plaque, and a useful entry point for therapeutic delivery. Moulton et al. 36 showed that anti-angiogenic therapy reduces the rate of plaque growth in the apolipoprotein E-insufficient mouse model of atherosclerosis. Administration of the antiangiogenic drug TNP-470, a water-soluble analog of fumagillin derived as a natural product of Aspergillus fumigatus fungus, at 30 mg/kg every other day for 16 weeks inhibited the plaque growth by 70%.
Along these lines, Winter et al. 52 utilized the cholesterol-fed rabbit model of early atherosclerosis to determine the efficacy of anti-angiogenic therapy. Rabbits on a high cholesterol diet were treated with one of three emulsions: a v b 3 -targeted fumagillin-loaded nanoparticles, a v b 3 -targeted nanoparticles without fumagillin, and non-targeted fumagillin-loaded nanoparticles. All three nanoparticle types included gadolinium so that MRI could be performed at treatment to assess the level of plaque angiogenesis as indicated by molecular imaging of a v b 3 -integrin expression, while simultaneously confirming and quantifying the specific binding of drug-laden nanoparticles, if targeted. One week later, all rabbits were re-imaged using diagnostic a v b 3 -targeted paramagnetic nanoparticles to evaluate the response of the a v b 3 -integrin, and hence the plaque neovasculature, to fumagillin therapy. The group that received the targeted anti-angiogenic nanoparticles exhibited a significant reduction in both the spatial distribution and level of a v b 3 -related signal enhancement; whereas the groups which received no drug or non-targeted drug-carrying nanoparticles exhibited no therapeutic effect (Fig. 8) . Histological analysis confirmed that neovasculature was concentrated in areas of the adventitia overlying regions of intimal thickening, and that neovasculature was significantly suppressed in those rabbits treated with a v b 3 -targeted anti-angiogenic nanoparticles. Furthermore, the T 1 -weighted MR image signal enhancement on the day of initial treatment with the a v b 3 -targeted anti-angiogenic paramagnetic nanoparticles predicted therapeutic responsiveness (or, reduced a v b 3 -integrin signal) on one-week follow-up MR imaging.
Targeted Thrombolytic Therapy
Thrombolysis is a clinical mainstay for rapid intervention in patients with acute myocardial infarction and stroke. However, serious systemic side effects can arise in the form of bleeding, hemorrhagic stroke, allergic reactions, and excitotoxicity. Although a number of modifications to active thrombolytic agents have been considered and tested to in an attempt to reduce side effects of drugs, such as streptokinase or tissue plasminogen activator (tPA), tPA remains the dominant agent in clinical use.
Marsh et al. 29 recently developed fibrin-targeted nanoparticles whose surfaces were modified to incorporate streptokinase, a traditional bacterial-derived thrombolytic enzyme that acts to convert plasminogen into its active fibrinolytic form, plasmin. The streptokinase was covalently coupled to the PFC nanoparticles with the use of 1.0 mol.% 1,2-dipalmitoyl-sn glycero-3-phosphoethanolamine-N-4-(p-maleimidophenyl)butyramide (MPB-PE; Avanti Polar Lipids) for coupling N-succinimidyl-S-acetylthioacetate (SATA)-derivatized streptokinase. Fibrin thrombi in vitro were targeted with the nanoparticles and imaged with high frequency ultrasound to illustrate binding based on enhanced acoustic backscatter from the clot surfaces, which permitted volumetric estimates. Profile backscatter plots of the detected clot surface demonstrated that streptokinase-loaded, fibrin-targeted nanoparticles in the presence of plasminogen induced rapid fibrinolysis in less than 60 min with nearly total loss of fibrin volume (Fig. 9) . In contrast, streptokinase-loaded or control fibrin-targeted nanoparticles incubated with buffer alone (i.e., no plasminogen available for conversion to plasmin) had no effect on clot volume over the course of the study. Morphologic changes exhibited in the treated group were accompanied by temporal and spatial changes in backscatter from the targeted surfaces indicative of the local action of the thrombolytic agent. This new nanoparticle-based thrombolytic agent may prove suitable for rapid and safe administration and could decrease the time from the ischemic event to reperfusion and lessen the morbidity and mortality of stroke.
In Vivo Targeted Anti-angiogenic Therapy for Cancer Anti-angiogenic agents for cancer have assumed a critical role in the therapeutic armamentarium for solid tumors subsequent to the demonstration of the efficacy of Avastin TM for various tumor types. 12, 15 Although a number of agents have been tested clinically, either lack of efficacy or systemic toxicity has limited their clinical adoption. To develop an approach that might deliver far more agent locally to intended sites of tumor angiogenesis by cell-selective contact-facilitated mechanisms, while simultaneously requiring far less systemic drug levels, Winter et al. 53 have utilized the a v b 3 -targeted fumagillin-loaded nanoparticles to suppress neovasculature and inhibit the growth of Vx-2 adenocarcinoma xenografts. Fumagillin, incorporated in minute doses into a v b 3 -targeted nanoparticles result in a decrease in Vx-2 tumor volume and a decrease in neovascular area without reticuloendothelial clearance organ toxiticy or neurocognitive dysfunction. Therapeutic efficacy for these targeted compounds was demonstrated at systemic doses that are 1000-fold lower than previous animal studies and 60-fold lower than has been tested clinically for related anti-angiogenic compounds (TNP-470).
CONCLUSIONS
Targeted perfluorocarbon ( 19 F) nanoparticles and other small molecule agents can offer unique and potentially quantitative signatures for molecular MRI and MRS with no competing background signal. Additionally, these perfluorocarbon nanoemulsions can be used to deliver lipophilic therapeutic agents in a site specific manner through contact mediated drug delivery while concurrently serving as direct confirmation of delivery via 19 F MRI/MRS. Multimodal imaging can be performed simultaneously, and multispectral detection with the use of different perfluorocarbons is possible. Sensitive image and spectral signal detection will benefit from improvements in both hardware and software as this nascent application moves into the clinical evaluation phase. 
